You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II

    SBC: TRANSLATIONAL SCIENCES INC            Topic: NHLBI

    This SBIR Application is responsive to NHLBI Small Business Topics of Special Interest (therapeutics) that are of high programmatic interest (HLS-17-04). Hemorrhage or bleeding is a serious or fatal complication of surgery. Antifibrinolytic agents that inhibit plasmin-mediated fibrinolysis can significantly reduce blood loss, emergency reoperation, morbidity and death in patients with severe hemor ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Targeting DNA damage response pathways for the treatment of advanced lung cancer

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 102

    ABSTRACTThere is an urgentunmet need for novel therapeutic approaches that are efficacious against lung cancerRanking first among cancer deaths in the U Sthis disease hasyear relative survival rates of andltMost lung cancers are non small cellNSCLCof casesCurative surgery is not an option for theof NSCLC patients who present with advanced stage III cancerFor these patients chemo radiation therapy ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Administrative Supplement to Promote Diversity in Research and Development Small Businesses

    SBC: NEUROENE THERAPEUTICS INC            Topic: NINDS

    Abstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Over-the-Wire Device for Immediate and Complete Peripheral Artery Occlusion

    SBC: Artio Medical, Inc            Topic: NHLBI

    ABSTRACT Metactive Medical is developing the Blockstent Microcatheteran innovative medical device for endovascular occlusion of peripheral arteries and veinsThe device uses an expandabledetachablegold metal balloon that can be delivered using a highly flexiblelow profileover thewire microcatheteraddressing an unmet medical need for a device that is easy to use and delivers immediatecompleteand las ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development of an Osteoinductive Spinal Fusion Implant for Enhanced Fusion Rates

    SBC: EVOKE MEDICAL LLC            Topic: NIAMS

    PROJECT SUMMARY The objective of this Phase II SBIR is to test the safety and efficacy of an osteoinductive lumbar spinal fusion implant in an ovine modelIn preliminary worklower impedance piezoelectric materials that generate power for direct currentDCelectrical stimulation applications were manufactured and electromechanically characterizedIn an osteoinductive spinal fusion implant designan insu ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Hierarchical, Layout-Aware, Radiation Effects Tools Vertically Integrated into an EDA Design Flow for Rad-Hard by Design

    SBC: RELIABLE MICROSYSTEMS LLC            Topic: DTRA16A003

    The goal of this workis to establish a radiation-aware capability in a commercial EDA design flow that will enable first-pass success in radiation resiliency for DoD ASIC designs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications.Such an integrated capability does not presently exist.The ...

    STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency
  9. Long non-coding RNA signatures to distinguish fibromyalgia syndrome from rheumatic diseases

    SBC: IQuity Labs, Inc.            Topic: R

    No other group of diseases encompasses a greater pathophysiology than do the rheumatic diseasesSpanning multiple organ systemsclinical decisions often rely on coordinated efforts from primary care providers and rheumatologists to rule in or rule out differential diagnoses when treating inflammatory conditions such as rheumatoid arthritisRAand systemic lupus erythematosusSLERA is a symmetricinflamm ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government